Name: Lexeo Therapeutics, Inc. (LXEO) Financial Statements
Creator: FinSpry

Lexeo Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Lexeo Therapeutics, Inc. income statement - Annual data in millions USD
Breakdown	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Revenue & Gross Profit
Revenue	0.00	-0.53	0.65	1.66	0.52
Cost of Revenue	0.00	53.13	49.16	45.12	4.32
Gross Profit	0.00	-0.53	-48.51	-43.46	-3.80
Operating Expenses
Research & Development	74.09	53.13	49.16	45.12	0.00
Selling, General & Administrative	31.68	15.38	12.00	7.17	0.79
Operating Expenses	105.77	68.51	61.16	52.29	0.79
Operating Income	-105.77	-68.51	-60.51	-50.64	-4.59
Other Income/Expense
Interest Income	7.56	2.87	1.33	0.02	0.00
Interest Expense	0.11	0.21	0.09	0.00	-0.15
Other Income/Expense	7.43	0.01	0.00	0.00	0.00
Income
Income Before Tax	-98.33	-66.39	-59.28	-50.62	-5.15
Income Tax Expense	0.00	0.00	0.00	0.00	0.00
Net Income	-98.33	-66.39	-59.28	-50.62	-5.15
Net Income - Continuous Operations	-98.33	-66.39	-59.28	-50.62	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-96.19	-64.38	-58.04	-50.61	0.00
EBIT	-98.21	-66.22	-59.19	-50.62	-4.59
Depreciation & Amortization	2.00	1.84	1.15	0.01	0.00
Earnings Per Share
Basic EPS	-3.00	-12.00	-2.00	-2.00	-4.00
Diluted EPS	-3.00	-12.00	-2.00	-2.00	-4.00
Basic Shares Outstanding	31.79	5.35	25.17	25.17	1.44
Diluted Shares Outstanding	31.79	5.35	25.17	25.17	1.44